Patent Application
20210269602
This application claims priority under 35 U.S.C. § 119 to Korean Patent Application No. 10-2020-0025077 filed on Feb. 28, 2020 in the Korean Intellectual Property Office, the disclosure of which is incorporated herein by reference in its entirety.
The present invention relates to a method for producing a stereocomplex polylactic acid composite based on oil-in-water emulsion blending, a method for preparing a drug delivery composition using a stereocomplex polylactic acid composite produced by the production method, and a drug delivery composition prepared by the preparation method.
Polylactic acid (PLA) or polylactide is a promising biodegradable polymer and exists as two different enantiomers, i.e. L- and D-forms, in nature. The two L- and D-form enantiomers combine to form a stereocomplex (sc) crystal. The resulting stereocomplex polylactic acid (sc-PLA) has greatly improved physical and mechanical strength as well as excellent thermal properties compared to the homopolymers. Based on these characteristics, environmentally friendly polymers based on the stereocomplex polylactic acid can be utilized as implantable materials and components that should withstand high external forces and pressures.
A stereocomplex polylactic acid is usually produced by solution blending, melt-blending or supercritical fluid technology. However, these conventional methods have many problems such as poor processability, low yield, low solubility, and high production cost. For example, solution blending is the easiest and widely used method because the process is very simple and readily accessible but has the disadvantages of very low stereocomplexation efficiency and long reaction time.
Melt-blending has the advantages of high stereocomplexation efficiency and short reaction time compared to solution blending but is disadvantageous in that since it induces the formation of a stereocomplex polylactic acid composite in a state in which the polymer is melted by heating, the molecular weight of the polymer is reduced and the original properties of the polymer are impaired. Supercritical fluid technology has the advantages of higher stereocomplexation efficiency, higher solubility, and much shorter reaction time than the other two methods. However, supercritical fluid technology involves an extremely complex process and uses high pressure, posing an increased danger.
(Patent Document 1) Korean Patent No. 10-1386399
The present invention has been made in an effort to solve the above problems, and one object of the present invention is to provide a method for producing a stereocomplex polylactic acid composite based on oil-in-water emulsion blending that has the advantages of short synthesis time and high stereocomplexation efficiency compared to solution blending, melt-blending or supercritical fluid technology.
A further object of the present invention is to provide a stereocomplex polylactic acid composite with high thermal stability and crystallinity.
Another object of the present invention is to provide a method for preparing a drug delivery composition using the stereocomplex polylactic acid composite.
Another object of the present invention is to provide a drug delivery composition that readily releases a drug at room temperature over a long period of time.
Objects of the present invention are not limited to the above-mentioned ones. The objects of the present invention will become more apparent from the following detailed description and will be implemented by means described in the claims and a combination thereof.
The present invention provides a method for producing a stereocomplex polylactic acid composite based on oil-in-water emulsion blending, including: (a) preparing a water phase solution including water and a first nonionic surfactant; (b) preparing an oil phase solution including poly(L-lactic acid) and poly(D-lactic acid); (c) dispersing the oil phase solution in the water phase solution while adding dropwise the oil phase solution at a rate of 1 to 200 μl/s to the water phase solution, to prepare an oil-in-water (O/W) emulsion; and (d) stirring the oil-in-water emulsion.
The water phase solution may be prepared by mixing the water with the first nonionic surfactant in a weight ratio of 1:0.01-0.5.
In step (b), the oil phase solution may be prepared by mixing the poly(L-lactic acid) with the poly(D-lactic acid) in a weight ratio of 1:9 to 9:1 for 1 minute to 3 hours or for 15 hours to 28 hours.
The oil phase solution may further include 0.1 to 10% by weight of a second nonionic surfactant, based on the total weight thereof.
The first nonionic surfactant and the second nonionic surfactant may be each independently selected from the group consisting of polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monooleate, polyoxyethylene lauryl ether, polyoxyethylene cetyl ether, polyoxyethylene oleyl ether, polyoxyethylene, and mixtures thereof.
In step (c), the oil-in-water (O/W) emulsion may be prepared by adding dropwise the oil phase solution at a rate of 15 to 80 μl/s to the water phase solution with a micropipette.
In step (d), the oil-in-water emulsion may be subjected to magnetic stirring at a speed of 100 to 1000 rpm.
The stereocomplex polylactic acid composite may be in the form of microspheres having an average particle diameter of 0.1 to 100 μm and may have a melting point of 200 to 280° C. and a stereocomplexation efficiency of at least 95%.
The water phase solution may be prepared by mixing the water with the first nonionic surfactant in a weight ratio of 1:0.03-0.08; the oil phase solution may be prepared by mixing the poly(L-lactic acid) with the poly(D-lactic acid) in a weight ratio of 5:5 for 1 minute to 5 minutes in step (b); the oil phase solution may further include 1 to 6% by weight of a second nonionic surfactant, based on the total weight thereof; each of the first nonionic surfactant and the second nonionic surfactant may be polyoxyethylene sorbitan monolaurate; and the oil-in-water (O/W) emulsion may be prepared by adding dropwise the oil phase solution at a rate of 20 to 50 μl/s to the water phase solution with a micropipette in step (c).
The present invention provides a stereocomplex polylactic acid composite produced by mixing an oil phase solution including poly(L-lactic acid) and poly(D-lactic acid) with a water phase solution including water and a nonionic surfactant and subjecting the mixture to oil-in-water emulsion blending wherein the stereocomplex polylactic acid composite is in the form of microspheres having an average particle diameter of 0.1 to 100 μm and has a melting point of 200 to 280° C. and a stereocomplexation efficiency of at least 95%.
The poly(L-lactic acid) may have a number average molecular weight (Mn) of 50,000 to 150,000 g/mol and the poly(D-lactic acid) may have a number average molecular weight (Mn) of 50,000 to 150,000 g/mol.
The stereocomplex polylactic acid composite may be a mixture of the poly(L-lactic acid) and the poly(D-lactic acid) in a weight ratio of 1:9 to 9:1.
The present invention also provides a method for preparing a drug delivery composition, including: (a) preparing a water phase solution including water and a first nonionic surfactant; (b) preparing an oil phase solution including poly(L-lactic acid), poly(D-lactic acid), and a drug; (c) dispersing the oil phase solution in the water phase solution while adding dropwise the oil phase solution at a rate of 1 to 200 μl/s to the water phase solution to prepare an oil-in-water (O/W) emulsion; and (d) stirring the oil-in-water emulsion to produce a stereocomplex polylactic acid composite loaded with the drug.
In step (b), the oil phase solution may be prepared by adding 0.1 to 33% by weight of the drug with respect to the total weight thereof, followed by mixing for 1 minute to 3 hours or for 15 hours to 18 hours.
The drug may be selected from the group consisting of fluorouracil (5-FU), capecitabine, cytarabine, gemcitabine, mercaptopurine, fludarabine, methotrexate, pemetrexed, and mixtures thereof.
The present invention also provides a drug delivery composition prepared by mixing an oil phase solution including poly(L-lactic acid), poly(D-lactic acid), and a drug with a water phase solution including water and a nonionic surfactant and subjecting the mixture to oil-in-water emulsion blending to produce a stereocomplex polylactic acid composite loaded with the drug wherein the stereocomplex polylactic acid composite is in the form of microspheres having an average particle diameter of 0.1 to 100 μm and has a melting point of 200 to 280° C. and a stereocomplexation efficiency of at least 95%.
The drug may be present in an amount of 0.1 to 33% by weight, based on the total weight of the drug delivery composition.
The drug may be selected from the group consisting of fluorouracil (5-FU), capecitabine, cytarabine, gemcitabine, mercaptopurine, fludarabine, methotrexate, pemetrexed, and mixtures thereof.
The stereocomplex polylactic acid composite of the present invention is produced using oil-in-water emulsion blending that has the advantages of simple process, short production time, and high stereocomplexation efficiency compared to existing methods such as solution blending, melt-blending, and supercritical fluid technology.
In addition, the drug delivery composition using the stereocomplex polylactic acid composite of the present invention is prepared using oil-in-water emulsion blending that allows the drug to be loaded into the polymer chains of the stereocomplex polylactic acid in a very easy and efficient manner and facilitates release of the drug at room temperature over a long period of time.
Effects of the present invention are not limited to the above-mentioned ones. It is should be understood that the effects of the present invention include all effects inferable from the following detailed description.
These and/or other aspects and advantages of the invention will become apparent and more readily appreciated from the following description of the embodiments, taken in conjunction with the accompanying drawings of which:
The present invention will now be described in more detail as one embodiment.
The present invention is directed to a method for producing a stereocomplex polylactic acid composite based on oil-in-water emulsion blending, a method for preparing a drug delivery composition using a stereocomplex polylactic acid composite produced by the production method, and a drug delivery composition prepared by the preparation method.
The present inventors have conducted research to overcome the limitations of conventional methods for preparing stereocomplex polylactic acid composites, and as a result, found that a stereocomplex polylactic acid composite can be produced using oil-in-water (O/W) emulsion blending while avoiding the limitations (including low stereocomplexation efficiency, low reaction speed, and complex processability) encountered in widely used methods such as solution blending, melt-blending, and supercritical fluid technology.
Specifically, the present invention provides a method for producing a stereocomplex polylactic acid composite based on oil-in-water emulsion blending, including: (a) preparing a water phase solution including water and a first nonionic surfactant; (b) preparing an oil phase solution including poly(L-lactic acid) and poly(D-lactic acid); (c) dispersing the oil phase solution in the water phase solution while adding dropwise the oil phase solution at a rate of 1 to 200 μl/s to the water phase solution, to prepare an oil-in-water (O/W) emulsion; and (d) stirring the oil-in-water emulsion.
The individual steps of the method according to the present invention will be described in detail.
Step (a)
In step (a), a water phase solution including water and a first nonionic surfactant is prepared. The first nonionic surfactant acts as an emulsifier that disperses the oil phase solution in the water phase solution to prepare an oil-in-water emulsion in the form of microspheres. The first nonionic surfactant is preferably one having a hydrophilic lipophilic balance (HLB) of 8 to 18. Specifically, the first nonionic surfactant can be selected from the group consisting of polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monooleate, polyoxyethylene lauryl ether, polyoxyethylene cetyl ether, polyoxyethylene oleyl ether, polyoxyethylene isooctylphenyl ether, and mixtures thereof. The first nonionic surfactant is preferably selected from the group consisting of polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monooleate, and mixtures thereof. Polyoxyethylene sorbitan monolaurate is most preferred as the first nonionic surfactant.
The water phase solution may be prepared by mixing the water with the first nonionic surfactant in a weight ratio of 1:0.01-0.5, preferably 1:0.02-0.1, more preferably 1:0.03-0.08, most preferably 1:0.05. If the weight ratio of the water to the first nonionic surfactant is 1:<0.01, the oil phase solution may not be uniformly dispersed, failing to prepare an oil-in-water emulsion in the form of microspheres. Meanwhile, if the weight ratio of the water to the first nonionic surfactant is 1:>0.5, the effect of the first nonionic surfactant to further disperse the oil phase solution cannot be expected.
Step (b)
In step (b), an oil phase solution including poly(L-lactic acid) and poly(D-lactic acid) is prepared. The poly(L-lactic acid) (PLLA) and the poly(D-lactic acid) (PDLA) are biodegradable oil phase polymers. Each of these components may be dissolved in an organic solvent such as methylene chloride before use.
The poly(L-lactic acid) has a number average molecular weight (Mn) of 50,000 to 150,000 g/mol, preferably 70,000 to 135,000 g/mol, more preferably 100,000 to 120,000 g/mol, most preferably 110,000 g/mol.
The poly(D-lactic acid) has a number average molecular weight (Mn) of 50,000 to 150,000 g/mol, preferably 105,000 to 140,000 g/mol, more preferably 110,000 to 130,000 g/mol, most preferably 120,000 g/mol. If the number average molecular weight of the poly(L-lactic acid) or the poly(D-lactic acid) is outside the range of 50,000 to 150,000 g/mol, high mechanical strength, melting point, and crystallinity of the stereocomplex polylactic acid composite cannot be expected.
In step (b), the oil phase solution may be prepared by mixing the poly(L-lactic acid) with the poly(D-lactic acid) in a weight ratio of 1:9 to 9:1 for 1 minute to 3 hours or for 15 hours to 28 hours. The weight ratio of the poly(L-lactic acid) to the poly(D-lactic acid) is 1:9 to 9:1, preferably 4:6 to 6:4, most preferably 5:5. Particularly, if the mixing weight ratio is not 5:5, the thermal stability or crystallinity of the stereocomplex polylactic acid composite may deteriorate significantly.
In step (b), the mixing time is limited to 1 minute to 20 minutes, preferably 1 minute to 10 minutes, most preferably 3 minutes to 5 minutes, to prevent the oil phase solution itself from inducing the production of the stereocomplex polylactic acid composite. This limitation allows the stereocomplex polylactic acid composite to have a very small average particle diameter of 10 μm or less, reduces the time it takes to produce the composite, and improves the crystallinity of the composite.
Alternatively, the mixing time may be in the range of 20 to 28 hours, preferably 22 to 26 hours, most preferably 23 to 25 hours. Within this range, the oil phase solution induces the production of the stereocomplex polylactic acid composite. In this case, the stereocomplex polylactic acid composite has an average particle diameter of 100 μm or less.
In step (b), the mixing time is preferably limited to 1 minute to 20 minutes to prevent the oil phase solution itself from inducing the production of the stereocomplex polylactic acid composite.
The oil phase solution may further include a second nonionic surfactant to further improve the dispersibility of the poly(L-lactic acid) and the poly(D-lactic acid). The second nonionic surfactant is used in an amount of 0.1 to 10% by weight, preferably 0.5 to 8% by weight, more preferably 1 to 6% by weight, most preferably 3% by weight, based on the total weight of the oil phase solution. If the amount of the second nonionic surfactant is less than 0.1% by weight, the effect of the second nonionic surfactant to further improve the dispersibility of the oil phase solution cannot be expected. Meanwhile, if the amount of the second nonionic surfactant exceeds 10% by weight, unreacted second nonionic surfactant may remain to hinder the production of the stereocomplex polylactic acid composite.
The second nonionic surfactant may be the same as the first nonionic surfactant. Specifically, the second nonionic surfactant can be selected from the group consisting of polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monooleate, polyoxyethylene lauryl ether, polyoxyethylene cetyl ether, polyoxyethylene oleyl ether, polyoxyethylene isooctylphenyl ether, and mixtures thereof. The second nonionic surfactant is preferably selected from the group consisting of polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monooleate, and mixtures thereof. Polyoxyethylene sorbitan monolaurate is most preferred as the second nonionic surfactant.
Step (c)
In step (c), the oil phase solution is dispersed in the water phase solution while adding dropwise the oil phase solution at a rate of 1 to 200 μl/s, preferably 10 to 150 μl/s to the water phase solution to prepare an oil-in-water (O/W) emulsion. The oil-in-water emulsion may consist of two types of emulsions. Preferably, the oil-in-water emulsion is a mixture of a poly(L-lactic acid) emulsion and a poly(D-lactic acid) emulsion. Rapid dropwise addition of the oil phase solution at a high rate of 1 to 200 μl/s to the water phase solution ensures homogeneity of the poly(L-lactic acid) emulsion and the poly(D-lactic acid) emulsion to induce the production of the stereocomplex polylactic acid composite having a uniform size.
The oil-in-water emulsion is prepared by adding dropwise the oil phase solution at a high rate, more preferably a rate of 15 to 80 μl/s, most preferably a rate of 20 to 50 μl/s, to the water phase solution with a micropipette. This dropwise addition makes the polymer chains of the stereocomplex polylactic acid composite smaller such that the stereocomplex polylactic acid composite has a small average particle diameter of 3 to 6 μm. A smaller and finer average particle diameter of the stereocomplex polylactic acid composite leads to higher crystallinity, thermal stability, and mechanical stiffness of the stereocomplex polylactic acid composite.
Step (d)
In step (d), the oil-in-water emulsion is stirred using a magnetic stirrer at 100 to 1000 rpm, preferably 600 to 900 rpm, most preferably 800 rpm. If the stirring speed is lower than 100 rpm, the poly(L-lactic acid) emulsion does not readily come into contact with the poly(D-lactic acid) emulsion, increasing the time it takes to produce the stereocomplex polylactic acid composite. Meanwhile, if the stirring speed exceeds 1000 rpm, excessive aggregation of the oil-in-water emulsion may be caused, resulting in a non-uniform particle size of the composite. The stereocomplex polylactic acid composite in the form of microparticles can be produced from the oil-in-water emulsion as a result of ring-opening polymerization between the poly(L-lactic acid) and the poly(D-lactic acid) at the water/oil phase interface. The stereocomplex polylactic acid composite is in the form of microspheres having an average particle diameter of 0.1 to 100 μm and has a melting point of 200 to 280° C. and a stereocomplexation efficiency of at least 95%.
Particularly, although not explicitly described in the Examples section that follows, stereocomplex polylactic acid composites were produced in the form of films by varying the components of the water phase solution and the oil phase solution, the mixing ratio between the water phase solution and the oil phase solution, the mixing time, the mixing speed, and the kind of the first nonionic surfactant and their elastic moduli, elongations, and tensile strengths were measured.
As a result, when the following conditions were all met, the stereocomplex polylactic acid composites were found to have improved crystallinities, resulting in increases in elastic modulus, elongation, and tensile strength, unlike when other conditions and other numerical ranges were employed. It was also found that the production times of the composites were considerably reduced and the production yields of the composites were improved.
(1) The water phase solution is mixed with the first nonionic surfactant in a weight ratio of 1:0.03-0.08, (2) the oil phase solution is prepared by mixing the poly(L-lactic acid) with the poly(D-lactic acid) in a weight ratio of 5:5 for 1 minute to 5 minutes in step (b), (3) the oil phase solution further includes the second nonionic surfactant, (4) the second nonionic surfactant is mixed in an amount of 1 to 6% by weight, based on the total weight of the oil phase solution, (5) each of the first nonionic surfactant and the second nonionic surfactant is polyoxyethylene sorbitan monolaurate, and (6) the oil-in-water (O/W) emulsion is prepared by adding dropwise the oil phase solution at a rate of 20 to 50 μl/s to the water phase solution with a micropipette.
When any one of the above six conditions was not met, unreacted polymers were melted and acted as impurities, the mechanical properties (including elastic moduli, elongations, and tensile strengths) of the stereocomplex polylactic acid composites deteriorated significantly, the production times of the stereocomplex polylactic acid composites increased, and the production yields of the stereocomplex polylactic acid composites dropped below 90%.
Although not explicitly described in the Examples section that follows, stereocomplex polylactic acid composites were produced that met the following conditions in addition to the above-mentioned conditions.
(7) The poly(L-lactic acid) has a number average molecular weight (Mn) of 100,000 to 120,000 g/mol and the poly(D-lactic acid) has a number average molecular weight (Mn) of 110,000 to 130,000 g/mol in step (b); (8) the oil-in-water emulsion is subjected to magnetic stirring at a speed of 600 to 900 rpm in step (d); and (9) the stereocomplex polylactic acid composite has an average particle diameter of 3.5 to 6 μm, a melting point of 215 to 240° C., and a stereocomplexation efficiency of at least 99%.
The stereocomplex polylactic acid composites did not lose their molecular weights even at high temperatures of 200° C. or more and their inherent characteristics were not impaired.
When any one of the above six conditions was not met, the polylactic acids were thermally degraded during polymerization at high temperature, resulting in a considerable reduction in molecular weight, and the composites lost their inherent characteristics, thus being unsuitable for use as implantable materials or components.
The present invention also provides a stereocomplex polylactic acid composite produced by mixing an oil phase solution including poly(L-lactic acid) and poly(D-lactic acid) with a water phase solution including water and a nonionic surfactant and subjecting the mixture to oil-in-water emulsion blending wherein the stereocomplex polylactic acid composite is in the form of microspheres having an average particle diameter of 0.1 to 100 μm and has a melting point of 200 to 280° C. and a stereocomplexation efficiency of at least 95%. The nonionic surfactant may be the same as the first nonionic surfactant.
The stereocomplex polylactic acid composite may have high thermal stability and improved physical and mechanical strength due to its high crystal melting point compared to the single-phase PLLA or PDLA. The stereocomplex polylactic acid composite has an average particle diameter of 0.1 to 100 μm, preferably 1 to 80 μm, more preferably 3 to 35 μm, most preferably 3.5 to 6 μm. The stereocomplex polylactic acid composite has a melting point of 200 to 280° C., preferably 210 to 260° C., more preferably 215 to 240° C., most preferably 230° C. The stereocomplex polylactic acid composite has a number average molecular weight of 50,000 to 400,000 g/mol, preferably 150,000 to 300,000 g/mol, most preferably 230,000 g/mol. The stereocomplex polylactic acid composite has a stereocomplexation efficiency of at least 95%, preferably at least 97%, most preferably at least 99%.
The poly(L-lactic acid) may have a number average molecular weight (Mn) of 50,000 to 150,000 g/mol and the poly(D-lactic acid) may have a number average molecular weight (Mn) of 50,000 to 150,000 g/mol. The stereocomplex polylactic acid composite may be a mixture of the poly(L-lactic acid) and the poly(D-lactic acid) in a weight ratio of 1:9 to 9:1.
The present invention also provides a method for preparing a drug delivery composition, including: (a) preparing a water phase solution including water and a first nonionic surfactant; (b) preparing an oil phase solution including poly(L-lactic acid), poly(D-lactic acid), and a drug; (c) dispersing the oil phase solution in the water phase solution while adding dropwise the oil phase solution at a rate of 1 to 200 μl/s to the water phase solution to prepare an oil-in-water (O/W) emulsion; and (d) stirring the oil-in-water emulsion to produce a stereocomplex polylactic acid composite loaded with the drug.
In step (b), the drug may be present in an amount of 0.1 to 33% by weight, based on the total weight of the oil phase solution and the mixing time may be 1 minute to 3 hours or 15 to 18 hours.
The drug is present in an amount of 0.1 to 33% by weight, preferably 1 to 33% by weight, 5 to 20% by weight, most preferably 5 to 10% by weight, based on the total weight of the oil phase solution. The presence of the drug in an amount exceeding 33% by weight may cause abnormal melting of the drug at around 75° C. and may inhibit the production of the stereocomplex polylactic acid composite.
The drug may be an anticancer agent. Specifically, the drug may be selected from the group consisting of fluorouracil (5-FU), capecitabine, cytarabine, gemcitabine, mercaptopurine, fludarabine, methotrexate, pemetrexed, and mixtures thereof. The drug is preferably selected from the group consisting of fluorouracil, capecitabine, mercaptopurine, and mixtures thereof. The drug is most preferably fluorouracil (5-FU). Fluorouracil (5-FU) is a drug that can be used to treat one or more cancers selected from the group consisting of breast cancer, colon cancer, rectal cancer, and pancreatic cancer. Fluorouracil (5-FU) has good thermal stability due to its high melting point (−282° C.).
In step (d), the oil-in-water emulsion is mixed using a magnetic stirrer at a high speed. This rapid mixing induces the production of the stereocomplex polylactic acid composite from the poly(L-lactic acid) and the poly(D-lactic acid) and enables the preparation of the drug delivery composition in which the stereocomplex polylactic acid composite is loaded with the drug. The drug can be infiltrated into the polymer chains of the stereocomplex polylactic acid during polymerization of the oil-in-water emulsion polymerization and can be loaded into the stereocomplex polylactic acid composite. The loaded drug can be released at room temperature over an extended period of 1 to 14 days.
The present invention also provides a drug delivery composition prepared by mixing an oil phase solution including poly(L-lactic acid), poly(D-lactic acid), and a drug with a water phase solution including water and a nonionic surfactant and subjecting the mixture to oil-in-water emulsion blending to produce a stereocomplex polylactic acid composite loaded with the drug wherein the stereocomplex polylactic acid composite is in the form of microspheres having an average particle diameter of 0.1 to 100 μm and has a melting point of 200 to 280° C. and a stereocomplexation efficiency of at least 95%.
The drug is present in an amount of 0.1 to 33% by weight, preferably 1 to 33% by weight, more preferably 5 to 20% by weight, most preferably 5 to 10% by weight, based on the total weight of the drug delivery composition.
The drug is loaded into the polymer chains of the stereocomplex polylactic acid and is easily released. Therefore, the drug delivery composition is applicable to a drug carrier.
As described above, the stereocomplex polylactic acid composite of the present invention is produced using oil-in-water emulsion blending that has the advantages of simple process, short production time, and high stereocomplexation efficiency compared to existing methods such as solution blending, melt-blending, and supercritical fluid technology.
In addition, the drug delivery composition using the stereocomplex polylactic acid composite according to the present invention is prepared using oil-in-water emulsion blending that allows the drug to be loaded into the polymer chains of the stereocomplex polylactic acid in a very easy and efficient manner simultaneously with the production of the stereocomplex polylactic acid, and facilitates release of the drug at room temperature over a long period of time. Furthermore, when one or more other substances are used in addition to the drug, secondary functions can be imparted to the stereocomplex polylactic acid-based polymer. Therefore, the present invention can greatly extend the application and utilization of polylactic acid, a representative environmentally friendly polymer.
The present invention will be more specifically explained with reference to the following examples but is not limited to these examples.
[Materials]
Poly(L-lactic acid) (PLLA) having a number average molecular weight (Mn) of 110,000 g/mol to 120,000 g/mol and poly(D-lactic acid) (PDLA) having a number average molecular weight (Mn) of 110,000 g/mol to 120,000 g/mol were used to produce stereocomplex polylactic acid composites by a classical ring-opening polymerization method. Then, each of the PLLA and the PDLA was dissolved at a concentration of 1 g/25 mL in methylene chloride (CH2Cl2) before use. 5-FU as an anticancer drug was purchased from Sigma Aldrich.
Preparation of Emulsion 1
25 ml of Tween 20 (polyoxyethylene sorbitan monolaurate) having an HLB of 16-17 as a first nonionic surfactant was mixed with 500 ml of deionized water to prepare a water phase solution. Then, the PLLA solution and the PDLA solution were mixed in a weight ratio of 5:5 and the mixture was added dropwise at a rate of 100 μl/s to the water phase solution at 25° C. to prepare an oil-in-water emulsion. Subsequently, the oil-in-water emulsion was stirred at a speed of 800 rpm using a magnetic stirrer to produce a stereocomplex polylactic acid composite. Thereafter, the stereocomplex polylactic acid composite was washed twice with distilled water to remove foreign contaminants and dried in a vacuum oven to remove the solvent.
Preparation of Emulsion 2
A water phase solution was prepared as described in the preparation of Emulsion 1. Then, the PLLA solution and the PDLA solution in a weight ratio of 5:5 were placed in an empty beaker and homogenized by magnetic stirring for 24 h to prepare an oil phase solution where the production of a stereocomplex polylactic acid composite was induced. As described in the preparation of Emulsion 1, the oil phase solution was mixed with the water phase solution to produce a stereocomplex polylactic acid composite, which was then washed and dried.
Preparation of Emulsion 3
A water phase solution was prepared as described in the preparation of Emulsion 1. Then, the PLLA solution and the PDLA solution in a weight ratio of 5:5 were placed in an empty beaker and homogenized by magnetic stirring for 3 min to prepare an oil phase solution where the production of a stereocomplex polylactic acid composite was not induced. As described in the preparation of Emulsion 1, the oil phase solution was mixed with the water phase solution to produce a stereocomplex polylactic acid composite, which was then washed and dried.
Preparation of Emulsion 4
A water phase solution was prepared as described in the preparation of Emulsion 1. Then, the PLLA solution and the PDLA solution in a weight ratio of 5:5 were placed in an empty beaker. 97 ml of the mixed solution was added with 3 ml of Tween 20 as a second nonionic surfactant and homogenized by magnetic stirring for 5 min to prepare an oil phase solution. As described in the preparation of Emulsion 1, the oil phase solution was mixed with the water phase solution to produce a stereocomplex polylactic acid composite, which was then washed and dried.
Preparation of Emulsion 5
A water phase solution and an oil phase solution were prepared as described in the preparation of Emulsion 3. Then, the oil phase solution was mixed with the water phase solution while adding the oil phase solution drop by drop (50 μl/s) to the water phase solution with a micropipette, to produce a stereocomplex polylactic acid composite. The stereocomplex polylactic acid composite was washed and dried, as described in the preparation of Emulsion 1.
The anticancer drug 5-FU was dissolved at a concentration of 50 mg/25 ml in propylene glycol. A water phase solution and an oil phase solution were prepared as described in the preparation of Emulsion 5. 20% by weight of the drug was added to 100% by weight of the oil phase solution in an empty beaker and homogenized by magnetic stirring for 3 min to prepare an oil phase solution where the production of a stereocomplex polylactic acid composite was not induced. As described in the preparation of Emulsion 5, the oil phase solution was mixed with the water phase solution using a magnetic stirrer at a high speed while adding the oil phase solution drop by drop (50 μl/s) to the water phase solution with a micropipette, to prepare a drug delivery composition including a stereocomplex polylactic acid composite loaded with the anticancer agent (sc-PLA/5-FU).
A stereocomplex polylactic acid composite was produced using the same components as described in Example 1, except that solution blending was used instead of oil-in-water emulsion blending.
A stereocomplex polylactic acid composite was produced using the same components as described in Example 1, except that conventional supercritical fluid (SCF) technology was used instead of oil-in-water emulsion blending.
Composite Using Solution Feed Supercritical Fluid Technology (SCF) A stereocomplex polylactic acid composite was produced using the same components as described in Example 1, except that conventional supercritical fluid (SCF) technology was used instead of oil-in-water emulsion blending.
The thermal properties and crystal structures of the stereocomplex polylactic acid composites produced in Example 1 were analyzed by thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), and wide-angle X-ray diffraction. 10 mg of the scPLA composite produced in Example 1 (Emulsion 5), 10 mg of the PLLA for comparison, and 10 mg of the PDLA for comparison were heated to 250° C. at a rate of 10° C./min and their thermal properties were measured by DSC. The results are shown in
The stereocomplexation efficiencies and synthesis times of the stereocomplex polylactic acid composites produced in Example 1 and Comparative Examples 1-3 were analyzed by TGA and DSC. Based on the DSC results, the stereocomplexation efficiency was calculated by the following equation:
Stereocomplexation efficiency (%)=ΔHm(sc-PLA)/ΔHm(Homopolymers),
where ΔHm(sc-PLA) is the enthalpy of melting for the stereocomplex polylactic acid (sc-PLA) composite and ΔHm(Homopolymers) represents the enthalpy of melting for the homopolymers PLLA and PDLA.
The results are shown in
As can be seen from
Proton nuclear magnetic resonance (1H-NMR) spectra and Fourier transform infrared (FTIR) spectra were recorded to determine whether the secondary anticancer agent 5-FU was loaded into the drug delivery composition (sc-PLA/5-FU) prepared in Example 2. The results are shown in
In
The time-dependent drug release profile of the drug delivery composition (sc-PLA/5-FU) prepared in Example 2 was analyzed by high-performance liquid chromatography (HPLC) to determine whether the composition indeed had an effect on the drug release. The results are shown in
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2020-0025077 | Feb 2020 | KR | national |
